The ARAF Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from HT29 human colorectal adenocarcinoma cells, providing a loss-of-function model for the ARAF serine/threonine-protein kinase. By disrupting the endogenous ARAF locus, this tool allows investigation of its specific functions within the RAS-RAF-MEK-ERK signaling cascade. The polyclonal format offers a heterogeneous pool of edited cells, capturing a spectrum of gene disruption efficiencies and enabling studies of overall phenotypic consequences without clonal isolation. This model is tailored for research in a colorectal cancer background where the BRAF V600E mutation creates a disease-relevant signaling context.
The HT29 cell line, established from a 44-year-old Caucasian female with colorectal adenocarcinoma, displays adherent epithelial morphology and is widely employed as an intestinal epithelial model for colorectal cancer research. These cells harbor the oncogenic BRAF V600E mutation, resulting in constitutive activation of the MAPK pathway and heightened sensitivity to perturbations in RAF isoform signaling. The well-characterized genetic profile and robust growth properties of HT29 make it an ideal host for evaluating ARAF knockout effects on proliferation, survival, and drug response.
ARAF encodes a serine/threonine kinase that functions as a core component of the RAS-MAPK phosphorylation cascade. It is activated by upstream GTPases HRAS, KRAS, and NRAS, which respond to receptor tyrosine kinases such as EGFR and VEGFR, as well as SRC family kinases. Upon activation, ARAF phosphorylates MAP2K1 (MEK1) and MAP2K2 (MEK2), which in turn phosphorylate MAPK3 (ERK1) and MAPK1 (ERK2). These ERK kinases then regulate transcription factors ELK1, FOS, and JUN to control gene expression programs governing proliferation, differentiation, and survival. ARAF activity is further modulated by interacting partners including the scaffold KSR1, chaperones HSP90 and CDC37, and 14-3-3 adaptor proteins YWHAE, YWHAB, and SFN, which influence its localization and enzymatic function.
In HT29 cells with the BRAF V600E mutation, ARAF may serve compensatory or non-overlapping roles, and its disruption is expected to reduce ERK pathway output, impair cell proliferation, and attenuate tumorigenic traits. This polyclonal knockout model permits dissection of ARAF’s contribution to oncogenic signaling in a context where other RAF isoforms are already pathologically activated. By comparing knockout cells with untreated or inhibitor-treated parental HT29 cells, researchers can evaluate functional redundancy among ARAF, BRAF, and RAF1, and identify circumstances in which ARAF is essential for tumor cell maintenance.
This cell product supports diverse research applications, including elucidation of ARAF-specific functions in colorectal cancer, examination of RAF isoform compensation during targeted therapy, and validation of ARAF as a drug target in resistant settings. Compatible assays include Western blotting for ARAF and phospho-MEK/ERK, RT-qPCR for ARAF mRNA, Sanger sequencing to detect CRISPR-induced indels, cell proliferation assays (MTT or BrdU), migration and invasion assays (Boyden chamber), apoptosis analysis with Annexin V/PI staining, and drug sensitivity testing using RAF inhibitors. For further technical details or experimental support, please contact Ascent Research.
